Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/5/2008

Conference Call Scheduled for November 6, 2008 at 10:00 a.m. EST

EAST BRUNSWICK, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three and nine months ended September 30, 2008. The net loss for the third quarter of 2008 was $18.2 million or $0.34 per basic and diluted share on total revenues of $0.5 million, compared with a net loss of $14.6 million or $0.28 per basic and diluted share on total revenues of $2.6 million for the same period in 2007. The net loss for the first nine months of 2008 was $60.0 million or $1.12 per basic and diluted share on total revenues of $2.1 million, compared with a net loss of $32.0 million or $0.61 per share on total revenues of $12.1 million for the same period in 2007. The company ended the quarter with $98.5 million in cash and short and long-term investments a reduction of $45.7 million from December 31, 2007.

"Our third quarter financial results were in line with expectations and represent our extensive efforts in preparing our Biologics License Application (BLA) that was recently filed with the FDA," said Christopher Clement, President and Chief Executive Officer. "Filing the BLA was a major milestone and brings us one step closer to commercializing pegloticase. We look forward to the possibility of changing the treatment paradigm for patients who suffer from this debilitating disease."

One recent highlight from the quarter is that our Biologics License Application for pegloticase was filed with the FDA on October 31, 2008. The filing included data from both the six-month placebo controlled Phase 3 pivotal trials, as well as the Open Label Extension (OLE) study. The BLA included 101 patients with at lea
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Savient Submits Biologics License Application (BLA) for pegloticase
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
4. Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
7. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
8. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
9. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
10. OncoMed Pharmaceuticals Completes Series B Financing
11. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company ... Philadelphia, PA. , The presentation took place on Tuesday, June 16 and ... the development of APX3330 for the treatment of pancreatic cancer. A copy of ...
(Date:6/30/2015)... July 1, 2015 R-Japan Co.,Ltd. obtained the license ... of Regenerative Medicine from the Ministry of Health, Labour and ... 2015. The fact that R- Japan ... the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on ... it to provide stem cell manufacturing service to medical institutions. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Park Systems , ... scientific research into new classes of Nanoscale Graphene-based materials poised to revolutionize industries ... wonder material of the 21st Century' by the researchers who were awarded the ...
(Date:6/30/2015)... YORK , June 30, 2015  Today, Americord Registry, ... U.S., announced Andrew Horne , a partner at Kirkland ... Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... to Americord,s Advisory Board," says Martin Smithmyer , CEO ... in his legal career that will assist Americord,s growth and ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... , -- Phase III trials of ... non-small cell lung cancer, expected to begin in 2010 ... oncology offerings with novel therapeutic designed to target resistance ... and VANCOUVER, Canada, Dec. 21 /PRNewswire-FirstCall/ - Teva Pharmaceutical ...
... METTLER ... In Situ FTIR Analytics as a Process Analytical Technology (PAT), on January 20, 2010. ... (PRWEB) December 20, 2009 -- ... Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT), on ...
... a polka-dotted postage stamp that can sniff out poisonous gases ... in the Sept. 13 issue of the journal Nature ... of Illinois have developed an artificial nose for the general ... and inexpensive and works by visualizing odors. This ...
Cached Biology Technology:Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 3Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 4Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 5Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 6Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 7Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 8Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... -- Fingerprint Cards has received an order of ... portfolio from one of its module partners in ... during the third quarter 2015. The sensors will be used ... Jörgen Lantto, CEO of FPC, comments: " This order ... from smartphone OEMs in integrating touch fingerprint sensors in   ...
Breaking Biology News(10 mins):Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... --- How do children reason about the natural world? ... non-human animals? For decades, the consensus was that ... they adopt an "anthropocentric" stance, favoring humans over non-human ... animals. But Northwestern University researchers have taken ...
... Southhampton and Cambridge Universities in the UK have presented ... in stronger hip bones. The results were presented at ... Italy. More than 200 six-year olds participated in ... bone mass and analysed the structure of the femoral ...
... as environmentally friendly sources of renewable energy, but which ... on developing? A new study involving researchers from North ... chemicals react when burned. Their data and new computer ... and technologies to maximize energy efficiency while minimizing environmental ...
Cached Biology News:Animals talk, sing and act like humans? 2Study paves way for new biofuels models, technologies 2
... collection and automation that is controlled from ... with Microsoft Excel , Pre-configured library ... density meters, force gauges, spectrophotometers, etc ... be added and configured by the user ...
... of calcium binding proteins such as calmodulin and ... alpha and beta chain whereas S100B is composed ... also expressed in the antigen presenting cells such ... reticulum cells in the paracortex of lymph nodes. ...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Biology Products: